269 related articles for article (PubMed ID: 14768754)
21. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
22. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.
Toner GC; Stockler MR; Boyer MJ; Jones M; Thomson DB; Harvey VJ; Olver IN; Dhillon H; McMullen A; Gebski VJ; Levi JA; Simes RJ
Lancet; 2001 Mar; 357(9258):739-45. PubMed ID: 11253966
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
24. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial.
Fizazi K; Do KA; Wang X; Finn L; Logothetis CJ; Amato RJ
Ann Oncol; 2002 Jan; 13(1):125-34. PubMed ID: 11863094
[TBL] [Abstract][Full Text] [Related]
25. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
[TBL] [Abstract][Full Text] [Related]
26. Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumours by optimizing combined treatment.
Pentheroudakis G; De Bono JS; Kaye SB; Simpson A; Paul J; Brown I; Pamenter B; Kirk A; Vasey P; Raby N; Kirk D
BJU Int; 2003 Jul; 92(1):36-42. PubMed ID: 12823380
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy for ovarian germ cell tumours.
Bower M; Fife K; Holden L; Paradinas FJ; Rustin GJ; Newlands ES
Eur J Cancer; 1996 Apr; 32A(4):593-7. PubMed ID: 8695258
[TBL] [Abstract][Full Text] [Related]
28. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
30. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
de Wit R; Stoter G; Sleijfer DT; Neijt JP; ten Bokkel Huinink WW; de Prijck L; Collette L; Sylvester R
Br J Cancer; 1998 Sep; 78(6):828-32. PubMed ID: 9743309
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).
Dearnaley DP; Fossa SD; Kaye SB; Cullen MH; Harland SJ; Sokal MP; Graham JD; Roberts JT; Mead GM; Williams MV; Cook PA; Stenning SP;
Br J Cancer; 2005 Jun; 92(12):2107-13. PubMed ID: 15928672
[TBL] [Abstract][Full Text] [Related]
32. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
[TBL] [Abstract][Full Text] [Related]
33. The management of poor-prognosis, non-seminomatous germ-cell tumours.
Sirohi B; Huddart R
Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):543-52. PubMed ID: 16238142
[TBL] [Abstract][Full Text] [Related]
34. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
Ledermann JA; Holden L; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD; Brampton M
Br J Urol; 1994 Aug; 74(2):225-30. PubMed ID: 7522874
[TBL] [Abstract][Full Text] [Related]
35. Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.
Azrif M; Leong YK; Aslan NM; Fong KV; Ismail F
Asian Pac J Cancer Prev; 2012; 13(6):2467-71. PubMed ID: 22938405
[TBL] [Abstract][Full Text] [Related]
36. [Combination chemotherapy with POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) in advanced non-seminomatous testicular tumor].
Masuda F; Kawahara M; Asano K; Shirakawa H
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1847-50. PubMed ID: 7574821
[TBL] [Abstract][Full Text] [Related]
37. POMB/ACE chemotherapy for mediastinal germ-cell tumours.
Droz JP
Eur J Cancer; 1997 May; 33(6):809-11. PubMed ID: 9291797
[No Abstract] [Full Text] [Related]
38. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
Behnia M; Foster R; Einhorn LH; Donohue J; Nichols CR
Eur J Cancer; 2000 Mar; 36(4):472-5. PubMed ID: 10717522
[TBL] [Abstract][Full Text] [Related]
40. Experience with bleomycin, etoposide, cisplatin (BEP) and alternating cisplatin, cyclophosphamide, doxorubicin (CISCA(II))/vinblastine, bleomycin (VB(IV)) regimens of chemotherapy in poor-risk nonseminomatous germ cell tumors.
Culine S; Théodore C; Bekradda M; Farhat F; Terrier-Lacombe MJ; Droz JP
Am J Clin Oncol; 1997 Apr; 20(2):184-8. PubMed ID: 9124197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]